United Therapeutics Corporation Overview
Pro stress-test →United Therapeutics is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. The company seeks to develop treatments for rare, deadly diseases and was founded in 1996 by a family seeking a cure for their daughter's pulmonary arterial hypertension. The firm operates as a public benefit corporation with a dual mission of delivering pharmaceutical therapies and expanding organ transplant availability.
Strategic Profile
Pro stress-test →Many of the company's products are focused towards lung disease and organ manufacturing. Key approved products include Orenitram, Remodulin, Tyvaso, and Tyvaso DPI for pulmonary arterial hypertension, with Tyvaso and Tyvaso DPI also indicated for pulmonary hypertension associated with interstitial lung disease. The pipeline includes gene therapy products like Aurora-GT and development-stage xenografts for organ replacement.
Competitive Landscape
Pro stress-test →Key competitors in the specialty drug manufacturing space include Neurocrine Biosciences (market cap $13.7B), Alkermes (market cap $4.7B), and Kiniksa Pharmaceuticals. United Therapeutics maintains competitive differentiation through its exclusive focus on transplantation and rare lung diseases, combined with proprietary xenotransplantation technology that has limited competition in the organ replacement market.
Industry Context
United Therapeutics Corporation operates in Biotechnology & Specialty Pharmaceuticals.
Key facts
Founded: 1996 · Headquarters: Silver Spring, Maryland · Employees: 1,168 · Revenue: $2.8B · Market cap: $22.9B